ANVISA grants marketing approval for Zylox-Tonbridge’s ZENFlow Tiger LD PTA Dilatation Catheter

Zylox-Tonbridge Medical Technology Co., Ltd., one of the leading players in the neuro-and peripheral-vascular interventional medical device market in China, announced that its ZENFlow Tiger LD PTA Dilatation Catheter, a product independently developed by the company, has received marketing approval from Brazilian Health Regulatory Agency (ANVISA). The company expects the launch of this newly approved product to provide a solid start to its business development in the South American market.

ZENFlow Tiger has several outstanding features. Its braided delivery shaft provides outstanding pushability and kink resistance, while the low-temperature molding technology ensures excellent non-compliance. With its unique tapered tip and short shoulder design, ZENFlow Tiger™ can facilitate access through complex lesions and maximize protection of normal blood vessels. Additionally, a coaxial catheter shaft design allows ZENFlow Tiger to inflate and deflate rapidly, and it is available in a wide range of sizes for different clinical needs.

The company also expects ZENFlow Tiger to show advantages in the treatment of various vascular diseases, such as iliac vein compression syndrome, Budd-Chiari syndrome, and other peripheral vascular occlusions. When this product is properly used in combination with mechanical thrombectomy devices and peripheral stents, the Company expects to see better treatment efficacy.

Driven by an aging population with greater awareness of treatment options, and the development of interventional technology, the peripheral vascular interventional devices market has continued to grow rapidly in recent years. By introducing ZENFlow Tiger into the Brazilian market, the Company expects to provide high-quality products and comprehensive solutions to local patients, and to continue to grow and succeed in its international business.

In 2023, Zylox-Tonbridge has made great progress in overseas markets. The Company generated a revenue of 6.23 million Yuan, representing a YOY increase of 128.7% during the first half of this year. As of the end of June, the Company’s products have been successfully commercialized in several developed overseas markets. Leveraging its strong R&D capabilities and advanced manufacturing platforms, the company also provided OEM services to local brands in some emerging markets.

Looking forward, Zylox-Tonbridge plans to continue investing in the international markets, providing patients worldwide with more innovative medical device products and solutions.

Zylox-Tonbridge is one of the leading players in the neuro- and peripheral-vascular interventional medical device market in China. The company was founded in 2012 and is headquartered in Hangzhou, China.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!